BTBP(SH:600161) 光大证券研究·2026-03-24 23:05Group 1 - The company announced on March 20, 2026, that its subsidiary, Tiantan Shanghai, received the "High-tech Enterprise Certificate," allowing it to enjoy a corporate income tax rate of 15% for three consecutive years (2025, 2026, 2027) [4] Group 2 - The company emphasizes innovation and R&D, with multiple products making significant progress. As of mid-2025, "Rongsheng" fourth-generation static gamma globulin received approval, while several other products are in various stages of clinical trials [5] Group 3 - The company maintains a leading position in plasma collection, achieving 1,361 tons of plasma collection from 85 operational plasma stations in the first half of 2025, accounting for approximately 20% of the domestic market [6] - The company has completed construction of several projects, including the Yong'an plant and Yunnan project, with a future design capacity for blood products exceeding 5,000 tons, ensuring continued leadership in production scale and sales revenue [6]